Market Overview

According to fortune business insights, the global genomics market was valued at USD 34.23 billion in 2025. The market is projected to grow from USD 38.24 billion in 2026 to USD 99.26 billion by 2034, exhibiting a CAGR of 12.66% during the forecast period. North America dominated the genomics market with a market share of 43.04% in 2025.

The analysis shows that the healthcare environment has gradually shifted from conventional treatment methods to precision medicine. The need for storage, sequencing, and analysis of large DNA information for the diagnosis and treatment of critical diseases such as cancer has significantly contributed to driving the market in recent years. This trend indicates strong growth for genomics worldwide.

Major Players Profiled in the Market Report:

• Illumina, Inc. (U.S.)
• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Agilent Technologies, Inc. (U.S.)
• Oxford Nanopore Technologies (U.K.)
• Danaher (U.S.)
• QIAGEN (Germany)
• BGI (China)
• IntegraGen (France)
• General Electric Company (U.S.)

Segments

Launch of New Software and Automated Sequencers to Foster Products Segment Growth

Based on type, the market is segmented into products and services. The products segment holds the largest market share due to high volume demand and usage of consumables, coupled with the introduction of new software and fully automated products to analyze large amounts of genetic information.

Widespread Use of PCR to Drive Technology Segment Growth

By technology, the market is categorized into polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, Sanger sequencing, and others. The PCR segment is leading the market, accounting for 47.25% of the market share in 2026, owing to its widespread use and availability.

High Demand in Clinical Applications to Drive Diagnostics Segment Expansion